Prof. Dr. Claudia Scholl
© dkfz.de
Prof. Claudia Scholl studied medicine at the Universities of Heidelberg and Ulm, and performed her medical thesis in the group of Prof. Döhner in the Department of Hematology, Oncology, Rheumatology and Infectious Diseases at the University Hospital of Ulm on the prognostic evaluation of genetic alterations in acute myeloid leukemia (AML). Following a two-year residency in Internal Medicine, she trained for four years as a postdoctoral fellow with D. Gary Gilliland at Brigham and Women's Hospital and Harvard Medical School in Boston, USA, supported by a stipend of the German Research Foundation (DFG). In May 2009, she returned to Ulm and continued her research as Junior Research Group Leader, which was funded in 2010 by the Emmy Noether Program of the DFG. In 2015 she was appointed as W3-Professor for Applied Functional Genomics at Heidelberg University, the German Cancer Research Center and National Center for Tumor Diseases Heidelberg, supported by the W2/W3 program for excellent female researchers of the Helmholtz Association. Since 2017, Prof. Scholl is head of the Division for Applied Functional Genomics at DKFZ. The overarching goal of her research is to identify new cancer drug targets through a better understanding of specific dependencies in human cancer cells by using targeted and genome-wide functional tools. Much of her research is centered around the identification of genetic vulnerabilities in cancers that carry mutations in the KRAS oncogene, and in AML.